SA
Log In
VNDA
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
18 analysts·Moderate coverage
67
Score
13 Buy (72%)4 Hold (22%)1 Sell (6%)
Rating Breakdown
Strong Buy
00%
Buy
1372%
Hold
422%
Sell
16%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$7.50
+1.5%
Consensus
$15.75
+113.1%
Bull
$24.00
+224.8%
12-Month Target Range18 analysts
$7.50$15.75$24.00
Current $7.39Consensus
Current Price
$7.39
Upside to Consensus
$8.36

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+37.74%
EPS—
FY2028
Rev+26.70%
EPS—
FY2029
Rev+28.59%
EPS+1630.00%

Earnings Surprises

Recent Analyst Actions

Feb 23, 2026H.C. Wainwright
Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright
Target:$24.00
+182.9%from $8.48
Jan 5, 2026H.C. Wainwright
Vanda Pharmaceuticals price target raised to $22 from $20 at H.C. Wainwright
Target:$22.00
+166.7%from $8.25
Dec 31, 2025Jefferies
Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies
Target:$7.50
+6.7%from $7.03
Nov 5, 2025B.Riley Financial
B.Riley Starts Vanda Pharmaceuticals (VNDA) at Buy
Target:$11.00
+152.9%from $4.35
Jul 11, 2024Cantor Fitzgerald
Vanda Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Target:$11.00
+111.1%from $5.21

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance